Protara Therapeutics, Inc. (TARA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.4400 |
| Open | 3.4500 |
| Bid | 3.3400 x 1100 |
| Ask | 3.6000 x 800 |
| Day's Range | 3.3700 - 3.6000 |
| 52 Week Range | 2.3780 - 5.7100 |
| Volume | |
| Avg. Volume | 24,554 |
| Market Cap | 37.971M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.0830 |
| Earnings Date | Mar 07, 2023 - Mar 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.75 |
- GlobeNewswire
Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York. The live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s w
- GlobeNewswire
Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer
NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Patrick Fabbio as Chief Financial Officer effective January 30, 2023. Mr. Fabbio most recently served as President and Chief Financial Officer at NYSE-listed Rafael Holdings, Inc. “We are excited to welcome Pat to the Protara leadership team,” said Jesse Shefferman, Chi
- GlobeNewswire
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCED-1 Phase 1 trial at the Annual Meeting of the Society of Urologic Oncology being held in San Diego, California from November 30, 2022 through December 2, 2022. The ADVANCED-1 study is evaluating TARA-002, an investiga
